Cereno has received notification from European High Growth Opportunities Securitization Fund regarding conversion of convertible bonds into 540 540 class B shares in Cereno, corresponding to SEK 2 000 000 of the convertible loan. The conversion price per share is SEK 3,7. Upon registration at the Swedish Companies Registration Office, Cereno’s total share capital will amount to SEK 1 216 416,3 and the total number of class B shares will amount to 12 164 163.
For more information, please contact:
Sten R. Sörensen – CEO
Tel: +46 733 74 03 74
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is a controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made available publically by the Company’s contact person on August 10th 2018.